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ABSTRACT
Background: Knowledge on the use of secondary preventive medication in young adults
is limited.
Methods: We included 936 first-ever ischemic stroke 30-day survivors aged 15–49, enrolled in
the Helsinki Young Stroke Registry, 1994–2007. Follow-up data until 2012 came from Finnish
Care Register, Statistics Finland, and Social Insurance Institution of Finland. Usage thresholds
were defined as non-users, low (prescription coverage <30%), intermediate (30–80%) and high
users (>80%). Adjusted Cox regression allowed assessing the association of usage with all-cause
mortality and recurrent vascular events.
Results: Of our patients, 40.5% were non-users, 7.8% had low usage, 11.8% intermediate usage
and 40.0% high usage. Median follow-up was 8.3 years. Compared to non-users, risk of mortality
and recurrent stroke or TIA was lower for patients with low-intermediate (HR 0.40, 95% CI
0.22–0.65; HR 0.31, 95% CI 0.18–0.53) and high usage (HR 0.25, 95% CI 0.15–0.42; HR 0.30, 95%
CI 0.19–0.46), after adjustment for confounders.
Conclusions: Use of antihypertensives was suboptimal in one-third of patients in whom antihy-
pertensives were initially prescribed. Users were at lower risk of mortality and recurrent stroke
or TIA compared to non-users.
KEY MESSAGES
 The use of antihypertensive medication is suboptimal in one-third of patients in whom anti-
hypertensive medication was initially prescribed after ischemic stroke at young age.
 The risk of mortality and recurrent stroke or TIA is lower for users of antihypertensive medica-
tion after ischemic stroke at young age compared to non-users, after adjustment for relevant
confounders including pre-existing hypertension and prior use of antihyperten-
sive medication.
 Specific guidelines on antihypertensive medication use after ischemic stroke at young age
are lacking. However, our results may motivate doctors and patients in gaining better usage
of antihypertensive medication, since better usage was associated with more favorable out-
come in this study.
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Introduction
Patients with an ischemic stroke (IS) at young age are
known to be at a substantial long-term risk of recur-
rent vascular events and death. One out of three will
be affected by recurrent vascular events and the risk
of mortality is 4-fold of expected, even up to 10 years
after the initial event [1–4]. Furthermore, the risk of
recurrence is found to be true-to-type, with high risks
of a recurrent IS in young IS patients [5]. As these
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diseases occur rather early in life, they incur high soci-
oeconomic costs for both the individual and the soci-
ety [6]. This warrants targeted aggressive
secondary prevention.
Antihypertensive therapy is proven to reduce the
rate of recurrent stroke, based on a number of
randomized, placebo-controlled trials [7–9]. However,
regular and lifelong use of antihypertensive medica-
tion in young adults is a particular challenge given the
life-long need for medication use, altered self-identity,
greater blood pressure variability compared to older
adults and possible side effects of medication [10].
There are no studies using longitudinal data exam-
ining factors influencing use of antihypertensive medi-
cation or the association between the use of
antihypertensive medication and recurrent vascular
events after stroke at younger ages. Data regarding
younger adults from randomized trials on antihyper-
tensive medication is lacking since few young adults
with IS have been included in these trials. Moreover,
guidelines on secondary prevention after stroke are
not specifically aimed at younger stroke patients.
In this study, we examined the association between
the use of antihypertensive medication and mortality
in young adults with IS, stratifying for etiologic sub-
groups. Secondary, we assessed the association
between the use of antihypertensive medication and
subsequent vascular events, including recurrent stroke
or TIA and vascular events other than stroke.
Methods
Data availability statement
Data cannot be shared for both legal and ethical rea-
sons. Data from Care Register for Health Care, the
National Institute for Health and Welfare and Statistics
Finland can only be used for the purpose stated in
the license granted, scientific research on society by
the license applicant, and can therefore not be shared
with third parties. However, we carefully documented
the data, methods and materials used to conduct the
research in this article. If one wishes to perform scien-
tific research and/or statistical surveys on society with
the data, one could apply for a license from these
institutions.
Study population
The Department of Neurology, Helsinki University
Hospital (HUH) has the only neurological emergency
unit for a population of 1.6 million inhabitants. All
1008 consecutive patients aged 15–49 years with a
first-ever IS treated in the Department of Neurology,
Helsinki University Hospital, from January 1994 to May
2007, were identified from a prospective computerized
hospital discharge database and were included in the
Helsinki Young Stroke Registry (HYSR). History of prior
stroke was based on medical records at the time of
the initial data collecting process. We used the defin-
ition of stroke given by the WHO, but also included
those patients with imaging-positive acute ischemic
findings in the brain region appropriate to clinical
presentation, even when the symptoms lasted less
than 24 h [11,12].
Baseline data
Baseline laboratory and other diagnostic tests have
been described in full previously [11]. We performed
computed tomography or magnetic resonance imag-
ing for all patients. Hypertension was defined as
treated hypertension or a history of hypertension
according to the 2003 World Health Organization cri-
teria [13]; systolic blood pressure (SBP) 140mm Hg
and/or diastolic blood pressure (DBP) 90mmHg [11].
Baseline blood pressure values were recorded at
admission and 24 h after admission, which are ought
to be only slightly higher than pre-morbid blood pres-
sure values [14]. We initially classified causes of stroke
using the Trial of Org 10172 in Acute Stroke
Treatment (TOAST) criteria [15], with further modifica-
tions revealing specific underlying causes in the cat-
egory of cardioembolism, using patient records, lab
records and imaging studies. Cardioembolic strokes
were divided into low-risk sources of cardioembolism,
which included patent foramen ovale and/or sole atrial
septal aneurysm, and high-risk sources of cardioembo-
lism, which included all other causes [16]. Moreover,
after introduction of criteria for embolic stroke of
undetermined source (ESUS) [17], we identified ESUS
patients among those with low-risk sources of cardi-
oembolism and TOAST undetermined etiology [18].
Non-ESUS cryptogenic included patients with stroke
with two or more causes identified, those with nega-
tive evaluation that did not fulfill ESUS criteria and
patients with incomplete evaluation. Furthermore, we
identified large-artery atherosclerosis (LAA), high-risk
source of cardioembolism (CEH) and small-vessel
occlusion (SVO) as “older-onset stroke causes” due to
the increasing incidences of these causes of stroke
with rising age [19], and other determined causes,
ESUS and non-ESUS cryptogenic causes as “young-
onset stroke causes”, due to the particularly high inci-
dences among younger patients. Stroke severity at
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admission was assessed with National Institutes of
Health Stroke Scale (NIHSS). We used patients’ voca-
tional status as a measure of socioeconomic status
(SES). SES was defined as upper-white-collar worker,
lower-white-collar worker, blue-collar worker, other
(unemployed, entrepreneur, student and
pensioner) and unknown SES, as described previ-
ously [6,20].
Follow-up data
Data on recurrent vascular events and mortality were
obtained from the Care Register for Health Care, from
the National Institute for Health and Welfare, Finland,
and from Statistics Finland, as described before [1].
Endpoints of interest were as follows: (1) all-cause
mortality; (2) composite endpoint including fatal/non-
fatal recurrent stroke of ischemic or hemorrhagic ori-
gin and transient ischemic attack (TIA), and (3)
composite endpoint of any fatal/nonfatal vascular
event including cardiac events including ACS, cardiac
death and other cardiac events as well as peripheral
arterial events, while excluding recurrent stroke of
ischemic or hemorrhagic origin and TIA. Follow-up
time started from the index stroke and ended on
December 31st, 2011, on the date of occurrence of an
endpoint of interest, or on the date of death, which-
ever occurred first [1].
We used the individually unique personal identifica-
tion codes of Finns to link our data to medication
records of the Drug Prescription Register kept by the
Social Insurance Institution of Finland. Data on the use
of antihypertensive medication was therefore gathered
retrospectively, similarly to other studies carried out in
Finland and Sweden [21,22]. All purchases used in the
treatment of hypertension within anatomical thera-
peutic chemical (ATC) classes [23] listed by the Finnish
Current Care Guideline were included. Consequently,
the following ATC codes were used to identify antihy-
pertensive medication: C02 (antihypertensive agents),
C03 (diuretic agents), C07 (beta-blocking agents), C08
(calcium channel blockers) and C09 (agents acting on
the renin–angiotensin system).
Antihypertensive treatment was indicated following
universally accepted goals and was based on both
national and international guidelines at the time of
inclusion. The general target was SBP of <140mmHg
and DBP of <90mmHg throughout the study period.
The first Finnish guidelines came in 2001 and recom-
mended SBP <140mm Hg and DBP <80mmHg in
patients with diabetes and SBP <130mmHg and DBP
<80mmHg in patients with proteinuria [24,25].
Patients were regarded to have an indication for anti-
hypertensive treatment if they had at least two pur-
chased prescriptions after admission to the hospital
due to index stroke. The rates of purchased prescrip-
tions are considered as accurate measures of the use
of antihypertensive medication in a closed pharmacy
system, such as in Finland, especially when the numer-
ous prescriptions are measured at several points in
time [26]. A physician writes all prescriptions in
Finland, providing the patient with access to the
medicine equal to a maximum use of 3 months
at once. Usage was defined as the proportion of fol-
low-up time covered by purchased prescriptions of
antihypertensive medication, calculating the number
of prescriptions needed and consequently comparing
that to the number of prescriptions purchased over
the entire follow-up period using the Proportion of
Days Covered method [27]. We defined usage thresh-
olds of <30% (low usage), 30–80% (intermediate
usage) and >80% (high usage), corresponding with
yearly medication purchases of none to 1, 2 and 3 or
more [21,26,28]. Patients without any purchased pre-
scriptions were considered as non-users. Individuals
who only had one purchase over the whole follow-up
period were removed from the analyses, as determin-
ing the indication was impossible.
Standard protocol approvals, registrations and
patient consents
We coded all data anonymously in the study database.
The local ethics committee approved the study proto-
col. Informed consent from patients in our cohort was
not needed according to Finnish legislation because
we did not contact patients or their caregivers.
Statistical analyses
We performed statistical analyses with IBM SPSS
Statistics, version 22.0 (SPSS Inc., IBM, Armonk, NY)
and the computer environment R (R Core Team, R
Foundation for Statistical Computing, Vienna, Austria,
2018). A P value of <0.05 was considered statistically
significant.
Kaplan–Meier curves with Log rank statistics
allowed univariate comparison of the risks of endpoint
events between usage groups.
First, we used Cox regression model to obtain haz-
ard ratios (HRs) and their corresponding confidence
intervals (CIs) as adjusted measures of rate ratios of
mortality to compare the different subgroups of use
of antihypertensive medication, with non-users as the
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reference category. We identified potential confound-
ers from previous literature [1,3,11], and consequently
adjusted for age, sex, types 1 and 2 diabetes mellitus,
cigarette smoking, heart failure, pre-existing hyperten-
sion, dyslipidemia, heavy drinking, contraceptive pill
use, modified TOAST classification, NIHSS at admission
and prior use of antihypertensive medication. In order
to create both comparable and powerful groups for
multivariate analysis, thresholds were limited to three
groups: non-users, low-intermediate usage and high
usage. Proportionality assumption was checked with
no violations observed. We did subgroup analyses
grouping typical older-onset stroke causes and typical
young-onset stroke causes as described before. We
also performed a sensitivity analysis on the main out-
come including only patients with pre-existing diagno-
sis of hypertension.
Second, to jointly assess the rate ratios of recurrent
stroke or TIA and vascular events other than stroke
among different subgroups of use of antihypertensive
medication, we used a marginal Cox regression model
for multiple outcomes [29]. The rate ratios were
adjusted for confounding using the same variables as
the Cox regression model assessing the rate ratios of
mortality. Proportionality assumptions were checked
with no violations observed. Subgroup analyses for
old- and younger onset causes of stroke were car-
ried out.
Finally, we calculated adjusted absolute risks (AR),
absolute risk reduction (ARR), and number needed to
treat (NNT) for each endpoint in the entire cohort by
using a logistic regression model, while adjusting for
the confounders mentioned before.
Results
Of the 1,008 patients enrolled in the HYSR, 10 were
lost to follow-up (could not be linked to registries),
four patients were excluded due to false primary diag-
nosis and 24 patients (median NIHSS 17.5) died within
30 days from the index stroke. After further exclusions,
936 patients were included in the analyses
(Supplementary Figure I). Patients were followed for a
median of 8.3 years (interquartile range 5.2–12.5), cor-
responding with a total of 8084.7 patient-years.
Baseline characteristics appear in Table 1. Of our
study population, 40.5% were non-users, 7.8% had low
use, 11.8% had intermediate use and 40.0% had high
use of antihypertensive medication. Regarding sex dif-
ferences, 34.3% of women and 43.3% men had high
usage, whereas 47.1% of women and 36.5% of men
were non-users (Supplementary Figure IIA). Of the
patients with history of hypertension, 75.7% had high
use of antihypertensive medication. However, 9.0% of
hypertension patients were non-users (Supplementary
Figure IIB). The proportion of high use slightly
decreased with rising socio-economic status, while
proportions of high use were the highest among
those with unknown socio-economic status
(Supplementary Figure III). There were larger propor-
tions of intermediate and high usage with increasing
age (Supplementary Figure IVA). Multiple cardiovascu-
lar risk factors (type 1 diabetes mellitus, congestive
heart failure, dyslipidemia and obesity) were signifi-
cantly associated (P< 0.001) with high usage, while
smoking and alcohol abuse were not. Furthermore,
proportions of patients using antihypertensive medica-
tion prior to their stroke were increasing among
patients with higher usage of antihypertensives after
their stroke (Supplementary Figure V).
Patients with older-onset stroke causes had a
higher proportion of high usage of antihypertensives
than patients with young-onset stroke causes
(Supplementary Figure IVB). Similar associations
emerged when assessing different etiologies separ-
ately for groups with and without hypertension
(Figure 1). Proportions of high usage were higher for
increasing baseline blood pressure values
(Supplementary Figure VI).
Of all classes of antihypertensive medication
assessed, agents acting on the renin-angiotensin sys-
tem (ATC class C09) were used in 53.2% of the
patients included and were therefore the most com-
monly used class of antihypertensive medication.
Combinations of two classes of antihypertensive medi-
cation were used by 15.8% of the patients, while
47.9% used three or more classes of antihypertensive
medication. An overview of crude numbers of the
endpoints among users of each type of antihyperten-
sive class is presented in Supplementary Table I.
Of all patients, 15.6% died, 17.1% experienced a
recurrent stroke or TIA and 17.5% experienced a recur-
rent vascular event other than stroke during follow-
up. Univariate comparison of the risks of endpoint
events between different antihypertensive usage
groups are shown in Figures 2–4. Numbers of
patients at risk for each analysis appear in
Supplementary Table II. Absolute risks, relative risks
and numbers needed to treat over time are shown in
Supplementary Table III. Compared to non-users, low-
intermediate usage and high usage were associated
with lower mortality in the fully adjusted Cox
Regression model (Table 2). Risks of recurrent stroke
or TIA were lower for low-intermediate and high
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usage, while low-intermediate and high usage were
associated with higher risks of vascular events other
than stroke in the fully adjusted Cox regression model
(Table 3). In the sensitivity analysis including only
patients with preexisting diagnosis of hypertension,
the main results were consistent (Supplementary
Table IV).
Compared to non-users, low-intermediate usage
and high usage were associated with lower mortality
in the fully adjusted Cox regression models in patients
with older-onset causes and young-onset causes of
their stroke (Table 2).
Low-intermediate usage was not associated with
lower risk of recurrent stroke or TIA, while high usage
was associated with lower risk of recurrent stroke or
TIA in patients with older-onset causes. In patients
with young-onset causes, low-intermediate and high
usage were associated with lower risk of recurrent
stroke or TIA (Table 3).
The use of antihypertensive medication was not
associated with lower risks of other recurrent vascular
event among patients with older-onset stroke causes
and was even associated with higher risks of other
recurrent vascular event in patients with young-onset
stroke causes (Table 3).
Discussion
The main findings of our study were the suboptimal
usage of antihypertensive medication in one-third of
Table 1. Selected baseline characteristics of the study population (n¼ 936) stratified by antihypertensive usage dur-
ing follow-up.
Non-users Low usage Intermediate usage High usage Total
n¼ 379 n¼ 73 n¼ 110 n¼ 374 n¼ 936
Age 41.0 (33.0–46.0) 42.0 (34.0–47.0) 45.0 (40.0–47.0) 45.0 (42.0–48.0) 44.0 (37.0–47.0)
Sex (male) 214 (56.5) 46 (63.0) 72 (65.5) 254 (67.9) 586 (62.6)
Risk factors
Active malignancy 8 (2.1) 0 (0.0) 0 (0.0) 2 (0.5) 10 (1.1)
Atrial fibrillation 10 (2.6) 1 (1.4) 1 (0.9) 23 (6.1) 35 (3.7)
Cigarette smoking 163 (43.0) 38 (52.1) 42 (38.2) 170 (45.4) 413 (44.1)
Congestive heart failure 6 (1.6) 2 (2.7) 2 (1.8) 34 (9.1) 44 (4.7)
Coronary heart disease 13 (3.4) 2 (2.7) 5 (4.5) 25 (6.7) 45 (4.8)
Dyslipidemia 188 (49.6) 49 (67.1) 69 (62.7) 262 (70.1) 568 (60.7)
Family history of stroke 47 (12.4) 5 (6.8) 13 (11.8) 54 (14.4) 119 (12.7)
Heavy drinking 53 (14.0) 15 (20.5) 16 (14.5) 46 (12.3) 130 (13.9)
History of TIA 23 (6.1) 3 (4.1) 10 (9.1) 45 (12.0) 81 (8.7)
Hypertension 34 (9.0) 14 (19.2) 44 (40.0) 287 (76.7) 379 (40.5)
Myocardial infarction 6 (1.6) 3 (4.1) 3 (2.7) 19 (5.1) 31 (3.3)
Type 1 diabetes mellitus 5 (1.3) 1 (1.4) 3 (2.7) 34 (9.1) 43 (4.6)
Type 2 diabetes mellitus 9 (2.4) 1 (1.4) 6 (5.5) 40 (10.7) 56 (6.0)
Obesity 13 (3.4) 9 (12.3) 11 (10.0) 70 (18.7) 103 (11.0)
Oral contraceptive use 43 (26.1)a 7 (25.9)a 6 (15.8)a 6 (5.0)a 62 (17.7)a
Peripheral artery disease 1 (0.3) 0 (0.0) 4 (3.6) 12 (3.2) 17 (1.8)
Prior use of antihypertensives 32 (8.4) 12 (16.2) 25 (22.7) 218 (58.4) 287 (30.7)
Stroke characteristics
Infarct sizeb
Small 147 (38.8) 37 (50.7) 45 (40.9) 191 (51.1) 420 (44.9)
Medium 113 (29.8) 23 (31.5) 35 (31.8) 90 (24.1) 261 (27.9)
Large anterior 68 (17.9) 7 (9.6) 13 (11.8) 52 (13.9) 140 (15.0)
Large posterior 51 (13.5) 6 (8.2) 17 (15.5) 41 (11.0) 115 (12.3)
Localization
Anterior 196 (51.7) 36 (49.3) 49 (44.5) 207 (55.3) 488 (52.1)
Posterior 173 (45.6) 33 (45.2) 54 (49.1) 151 (40.4) 411 (43.9)
Both anterior and posterior 10 (2.6) 4 (5.5) 7 (6.4) 16 (4.3) 37 (4.0)
Multiple territories 13 (3.4) 5 (6.8) 6 (5.5) 22 (5.9) 46 (4.9)
Stroke severity (NIHSS at admission) 3.0 (1.0–7.0) 3.0 (1.0–6.0) 2.0 (1.0–5.0) 3.0 (1.0–5.0) 3.0 (1.0–6.0)
Stroke etiology (modified TOAST)
Large artery atherosclerosis 19 (5.0) 3 (4.1) 8 (7.3) 40 (10.7) 70 (7.5)
High-risk sources of cardioembolism 16 (4.2) 5 (6.8) 8 (7.3) 56 (15.0) 85 (9.1)
Small-vessel occlusion 12 (3.2) 2 (2.7) 17 (15.5) 106 (28.3) 137 (14.6)
Other causes 123 (32.5) 18 (24.7) 29 (26.4) 78 (20.9) 248 (26.5)
Non-ESUS cryptogenic 100 (26.4) 27 (37.0) 29 (26.4) 47 (12.6) 203 (21.7)
ESUS 109 (28.8) 18 (24.7) 19 (17.3) 47 (12.6) 193 (20.6)
Data are n (%) or median (interquartile range). TIA: transient ischemic attack; NIHSS: National Institutes of Health Stroke Scale; TOAST: Trial of Org 10172
in Acute Stroke Treatment; ESUS: embolic stroke of undetermined source
aWithin female patients. bThe size of a small infarct was a 1.5 cm lesion in the anterior or posterior circulation, or no visible lesion. A medium infarct
was a lesion in the cortical superficial branch of the anterior cerebral artery, middle cerebral artery, posterior cerebral artery, or in a deep branch of
middle cerebral artery or posterior cerebral artery, or lesion in internal border zone territories. A large anterior infarct was a lesion involving complete
territory of anterior cerebral artery or middle cerebral artery or lesion involving >1 arterial territory, and a large posterior infarct a >1.5 cm lesion
involving brain stem or cerebellum or involving complete territory of posterior cerebral artery together with border zone territories.[1]
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Figure 1. Association between modified TOAST categories and use of antihypertensive medication for patients (A) with and (B)
without hypertension
non-users
(A) (B) (C)
high usage low-intermediate usage
Figure 2. Kaplan Meier curves of the study population for (A) all-cause mortality (B) recurrent stroke or TIA and (C) other recur-
rent vascular event
(A) (B) (C)
non-users high usage low-intermediate usage
Figure 3. Kaplan Meier curves of patients with older-onset causes of their stroke for (A) all-cause mortality (B) recurrent stroke or
TIA and (C) other recurrent vascular event
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all users after IS at young age and the lower risk of
mortality and recurrent stroke or TIA in antihyperten-
sive users compared to non-users after adjustment for
relevant confounders. Specific guidelines on antihyper-
tensive medication use after young IS are lacking.
However, our results may motivate doctors and
patients in gaining better usage of antihypertensive
medication, since better usage was associated with
more favorable outcome in this study.
In our study, higher proportion of antihypertensive
use and better usage appeared with increasing age,
which is in accordance with previous studies on gen-
eral population [10,30,31]. We also found presence of
cardiovascular risk factors to be associated with higher
frequency of antihypertensive users with higher usage,
corresponding with earlier findings and suggesting
that patients with severe clinical conditions are more
willing to follow a therapeutic regimen [32,33]. We did
not find an association between lower SES and lower
use of antihypertensive medication, which is in accord-
ance with previous research [34].
We found usage of antihypertensive medication
to be associated with mitigated risks of all-cause
mortality and recurrent stroke or TIA when com-
pared with non-users, corresponding with significant
risk reduction during follow-up. This association was
independent of demographics, preexisting hyperten-
sion, prior use of antihypertensive medication, other
comorbidities and stroke subtype, underlining the
importance of antihypertensive medication in the
secondary prevention of stroke in young adults.
Adjusted absolute risk reduction of mortality after 1
year of follow-up was 32.9% in high-using patients
compared to non-users. Over-all risk of mortality
after 1 year of follow-up was found to be 4.7%,
which might be reduced by the use of antihyperten-
sive medication after stroke at young age [35].
Previous studies found significant differences
(A) (B) (C)
non-users high usage low-intermediate usage
Figure 4. Kaplan Meier curves of patients with young-onset causes of their stroke for (A) all-cause mortality (B) recurrent stroke
or TIA and (C) other recurrent vascular event
Table 2. Fully adjusted hazard ratios of all-cause mortality,
non-users as reference category.
HR 95% CI p
Study population (n¼ 936)
Non-users 1 NA NA
L-I 0.40 0.22–0.65 <.001
H 0.25 0.15–0.42 <.001
Older-onset stroke causes (n¼ 292)
Non-users 1 NA NA
L-I 0.26 0.11–0.62 .002
H 0.18 0.09–0.35 <.001
Young-onset stroke causes (n¼ 644)
Non-users 1 NA NA
L-I 0.38 0.19–0.79 .010
H 0.37 0.16–0.82 .015
HR: hazard ratio with non-users as the reference category; CI: confidence
interval; H: high usage; L-I: low-intermediate usage; NA: not applicable;
TIA: Transient Ischemic Attack.
Table 3. Fully adjusted hazard ratios of recurrent TIA/stroke
and other recurrent vascular events, non-users as refer-
ence category.
HR 95% CI p
Study population (n¼ 936)
Recurrent stroke or TIA Non-users 1 NA NA
L-I 0.31 0.18–0.53 <.001
H 0.30 0.19–0.46 <.001
Other recurrent vascular event Non-users 1 NA NA
L-I 2.02 1.03–3.95 .040
H 2.03 1.26–3.26 .004
Older-onset stroke causes (n¼ 292)
Recurrent stroke or TIA Non-users 1 NA NA
L-I 0.50 0.22–1.14 .099
H 0.28 0.15–0.52 <.001
Other recurrent vascular event Non-users 1 NA NA
L-I 0.81 0.27–2.47 .714
H 1.51 0.67–3.44 .324
Young-onset stroke causes (n¼ 644)
Recurrent stroke or TIA Non-users 1 NA NA
L-I 0.20 0.09–0.46 <.001
H 0.40 0.21–0.79 .008
Other recurrent vascular event Non-users 1 NA NA
L-I 3.68 1.41–9.65 .008
H 1.47 0.74–2.91 .268
HR: hazard ratio with non-users as the reference category; CI: confidence
interval; H: high usage; L-I: low-intermediate usage; NA: not applicable;
TIA: Transient Ischemic Attack.
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between low and high adherence to antihyperten-
sive medication benefitting the patients with high
adherence regarding risks of any recurrent cardiovas-
cular event. However, these studies included an older
population of patients diagnosed with hypertension,
which might be the reason that we did not find lower
risks for recurrent vascular events among any users of
antihypertensive medication [32,36]. Higher risks of
recurrent events other than stroke or TIA among
users of antihypertensive medication might have sev-
eral explanations. First, high-using patients might
have more cardiovascular risk factors and are there-
fore willing to follow a therapeutic regimen, but are
at a initial higher risk of vascular events.
Second, these patients might have a treatment-resist-
ant early-onset diagnosis of hypertension or second-
ary hypertension, causing the higher risk of other
recurrent vascular events. However, absolute num-
bers of events are low for other recurrent vascular
events, and thus caution is warranted when interpret-
ing this finding.
Our study also showed significant differences
between patients grouped into young-onset and
older-onset causes. Antihypertensive users with both
young-onset and older-onset causes of their stroke
had lower risks of all-cause mortality than non-users,
underlining the importance of antihypertensive
medication as secondary prevention after stroke. The
risk of recurrent stroke or TIA was lower for high
usage compared to non-users in patients with older-
onset causes of their stroke, while the risk of recur-
rent TIA or stroke was not lower for low-intermediate
usage. This corresponds with previous findings of
higher risks of recurrent (fatal) stroke with a stepwise
decline in usage in an older population with high
prevalence of these etiologies [21]. Consequently,
this strengthens the view that to reduce the risk of a
recurrent stroke or TIA in patients with LAA, CEH or
SVO, high usage of antihypertensive medication
might be essential. However, these patients may
have been exposed to the beneficial effects of other
(secondary) preventive therapies, an aspect we were
not able to analyze in this study. In addition, we
were unable to reliably analyze specific TOAST sub-
groups due to low numbers and thus our data are
not directly generalizable to specific etiologies. Both
low-intermediate and high-adherent antihypertensive
users with young-onset causes of their stroke were
at lower risk of experiencing a recurrent stroke or
TIA compared with non-users. However, the risk of
other recurrent vascular event was not lower for
patients with older-onset stroke causes, and even
higher among patients with young-onset stroke
causes compared to non-users. This might be
explained by higher use of antihypertensive medica-
tion among patients with more cardiovascular risk
factors, or among patients with other indications for
antihypertensive medication, which are not included
in this study.
The strengths of our study include a large non-
selected study population with long follow-up,
multiple endpoints and registry-based source-data
verified outcome data, with only 0.1% loss to follow-
up. In addition, our registry contains virtually all
young stroke patients from the HUH catchment area
[11]. Therefore, our study population is a good sam-
ple to represent the population of young stroke
patients. Furthermore, the data obtained from the
Drug Prescription Register can be considered as
accurate measures of the usage of medication, as
Finland has a closed pharmacy system and data on
prescriptions are kept at several points in time and
are available for clinicians and researchers [28]. As
we used marginal Cox regression model for multiple
outcomes to assess the outcomes other than mortal-
ity, there were no competing risks in the analyses, as
patients could experience both endpoints in the
model used. Furthermore, the analysis assessing rate
ratios of mortality among different usage groups of
antihypertensive medication was ran separately, tak-
ing all causes of mortality into account.
Consequently, there were no competing risks for
mortality as well.
This study also has limitations. First, the end-
points of interest in this study were registry-based,
leaving a possibility of selection bias and misclassifi-
cation of events. The positive predictive value and
sensitivity of the registries used to obtain data on
the endpoints of interest have been fairly good for
both fatal as non-fatal cardiovascular events,
although validation of recurrent strokes is lacking for
patients aged 15–25 years [37–39]. Furthermore, the
events of interest of the present study virtually
always lead to hospitalization in Finland. Second, the
diagnostic and etiologic workup, including the use
of MRI and vessel imaging, has evolved during the
inclusion period of the cohort. By excluding patients
with only one prescription, the proportion of non-
users or low usage might have been underestimated.
In addition, it is important to stress that although
the data on prescriptions with a purchase of antihy-
pertensive medication is objective and are collected
routinely, they do not measure the actual intake of
these medications, leading to a possible
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underestimation of the proportion of low usage,
intermediate usage or even non-users [21]. However,
high concordance between prescriptions and the
golden standard of measuring medication adher-
ence, the Medication Event Monitoring System, indi-
cates that the rate of purchased prescriptions is in
line with the rate of consuming by the patients [40].
As this study was registry-based, indications other
than hypertension for prescribing antihypertensive
medication could not be determined, which might
have influenced our results. Moreover, clinical data
on the indication of antihypertensive medication
during the follow-up period was not available as
patients did not have clinical follow-ups during the
follow-up period in this registry-based study.
Therefore, we were not able to determine whether a
patient lost indication for antihypertensive medica-
tion during the follow-up period and could conse-
quently not assess any side effects that lead to
discontinuation. In addition, as medication usage is
not the same as optimal blood pressure control, dif-
ferences in blood pressure control in the same usage
categories might have affected the results. However,
as this study is registry-based, data on blood pres-
sure control was not available. Finally, possible rea-
sons for high adherence include high stroke severity,
as medication might be provided by the hospital.
However, high stroke severity might as well lead to
lower adherence, as secondary prevention could
have been stopped in palliative care settings. To fully
assess if NIHSS influenced the results, we ran the
analyses with and without NIHSS as a covariate, after
which the results did not differ significantly, suggest-
ing that NIHSS score did not account for the differ-
ences in outcomes among users compared to non-
users of antihypertensive medication.
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